Potential breakthrough for patients with relapsed or refractory large B-cell lymphoma – Parker Institute for Cancer Immunotherapy

Yan Leyfman, Co-Founder and Executive Director at MedNews Week,  shared a posted by Parker Institute for Cancer Immunotherapy, on LinkedIn:

“So does that mean that CD22 could be a better target than CD20 or does this suggest that we need molecular profiling to decide which patients would respond best to which type of therapy?”

Quoting Parker Institute for Cancer Immunotherapy‘s post:

“New results from a phase 1 clinical trial led by Stanford researchers, including Crystal Mackall, MD, PICI Center Director, at Stanford University School of Medicine, and published in The Lancet reveal a potential breakthrough in cancer immunotherapy for patients with relapsed or refractory large B-cell lymphoma (LBCL). The study focused on CAR22 T-cell therapy, a type of immunotherapy in which a patient’s T-cells are engineered to produce a chimeric antigen receptor (CAR) designed to recognize and bind to the CD22 protein on cancer cells. This innovative therapy presents a new avenue for patients who have exhausted other treatment options, including similar therapies targeting the CD19 protein, which have shown limited efficacy in this patient population.

The trial results were remarkable, with 68% of patients responding to CAR22 T-cell therapy and 53% achieving complete remission – a significant outcome for this resistant form of cancer. Notably, the treatment was well-tolerated, with a lower incidence of severe side effects compared to other CAR T-cell therapies. These promising findings from the team at Stanford pave the way for an expanded, multi-center study to further evaluate the efficacy and safety of CAR22, potentially reshaping the treatment landscape for LBCL and providing a much-needed lifeline for patients who previously had few options.

→ Explore the full paper in The Lancet.
→ Read the news article from Stanford.
→ Hear more about Dr. Mackall on our From Bench to Fireside.”

Source: Yan Leyfman/LinkedIn and Parker Institute for Cancer Immunotherapy/LinkedIn